Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Urticaria Market Revenue Outlook: What CAGR Is Expected Through 2030?
The urticaria sector experienced a significant expansion during the recent past period. Projections indicate a continued upward trajectory, with market value anticipated to escalate from $4.76 billion in the year 2025 to $5.61 billion by 2026, reflecting a compound annual growth rate (CAGR) of 17.9%. Factors contributing to this growth during the preceding period include a rise in the incidence of allergic skin ailments, increased utilization of antihistamine medications, a broader availability of dermatological treatment options, heightened public understanding of chronic urticaria, and the accessibility of prescription-based therapeutic interventions.
The global urticaria market is poised for substantial expansion, projected to reach $10.71 billion by the year 2030, reflecting a robust compound annual growth rate (CAGR) of 17.5%. This anticipated surge is underpinned by several key factors, including the escalating adoption of biologic medications, a growing preference for extended-release treatment options, and an increased emphasis on the development and application of immune-modulating drugs. Furthermore, the proliferation of specialized dermatology centers and augmented investments in research pertaining to allergies and immunology are expected to significantly contribute to market growth. During this forecast period, dominant trends are anticipated to involve the advancement of biologic and monoclonal antibody treatments, a greater utilization of tailored therapeutic strategies, a heightened focus on the comprehensive management of chronic urticaria, the introduction of more sophisticated antihistamine formulations, and an overarching drive towards achieving sustained control over the condition.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23554&type=smp
Urticaria Market Growth Drivers And Industry Catalysts
Heightened consciousness regarding skin ailments and their management is anticipated to propel the urticaria market’s expansion. Escalating pollution levels contribute to a rise in skin allergies and related conditions, consequently amplifying the need for awareness campaigns and sophisticated treatment modalities. Urticaria plays a role in advancing public knowledge and medical intervention for skin diseases by illustrating immune system reactions, stimulating scientific investigation, refining diagnostic capabilities, and fostering the development of specialized treatments. An example illustrating the broader context of skin health was the February 2024 report from The Skin Cancer Foundation, a non-profit organization in the United States, which indicated that one-fifth of Americans will be diagnosed with skin cancer by the age of 70, with mortality occurring hourly across the U.S., underscoring the critical importance of proactive strategies, given that experiencing five or more instances of sunburn significantly elevates the likelihood of developing melanoma. Thus, a growing emphasis on recognizing and treating skin diseases is a key factor fueling the urticaria market’s growth.
Urticaria Market Segment Analysis: What Are The Major Market Categories?
The urticaria market covered in this report is segmented –
1) By Type: Acute Urticaria, Chronic Urticaria
2) By Drug Class: Antihistamines, Anti-inflammation Medications, Antidepressants, Monoclonal Antibodies, Other Drug Classes
3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Acute Urticaria: Allergic Urticaria, Infectious Urticaria, Drug-Induced Urticaria, Contact Urticaria
2) By Chronic Urticaria: Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU)
#Urticaria Market Trends Influencing Long-Term Demand
Within the urticaria sector, key players are concentrating on pioneering advancements, notably the creation of mast cell inhibitor antibodies, as a sophisticated approach to chronic spontaneous urticaria treatment by mitigating mast cell activity. These inhibitor antibodies represent a specialized form of monoclonal antibody engineered to impede the activation or release of substances from mast cells, accomplished through the blockade of particular receptors or intercellular communication routes, which consequently diminishes allergic responses, inflammatory processes, and other conditions driven by mast cells. Illustrating this trend, in May of 2024, Allakos Inc., a biotechnology firm situated in the United States, commenced a Phase 1 clinical evaluation for AK006, a treatment candidate intended for chronic spontaneous urticaria (CSU). This novel therapeutic agent is formulated to address both IgE-dependent and IgE-independent mechanisms of mast cell activation, potentially yielding superior effectiveness in individuals unresponsive to antihistamines or preceding biological therapies. Through its specific obstruction of mast cell function via the Siglec-6 receptor, AK006 endeavors to deliver a more thorough and enduring resolution for CSU, signaling a notable leap forward in both urticaria care and the field of immunotherapy investigation.
Urticaria Market Leading Companies Driving Competitive Growth
Major companies operating in the urticaria market are Sanofi S.A., Novartis AG, GlaxoSmithKline PLC, Roche Holding AG, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Incyte Corporation, Kyowa Kirin Co. Ltd, Argenx SE, Allakos Inc, AstraZeneca plc, Kiniksa Pharmaceuticals Ltd, United BioPharma Inc, Celldex Therapeutics Inc, Yuhan Corporation, Hangzhou Highlightll Pharmaceutical Co Ltd, Evommune Inc, Rapt Therapeutics Inc, Enanta Pharmaceuticals Inc, UCB Pharma
Access The Complete Urticaria Market Report:
https://www.thebusinessresearchcompany.com/report/urticaria-global-market-report
Urticaria Market Largest Region By Revenue And Market Share
North Americawas the largest region in the urticaria market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the urticaria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
